The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | DREAMM-5: belamaf therapy in R/R myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, introduces the DREAMM-5 trial (NCT04126200) which explores the use of belantamab mafodotin (Belamaf) in combination with four different novel agents in relapsed/refractory multiple myeloma (R/R) myeloma. Belamaf’s multimodal mechanism of action has the potential to achieve synergistic effects when combined with these other agents; enhancing anti-myeloma activity without compromising safety. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
